SIGA 10-Q: Q3 Revenue $1.3M, Net Loss $2.9M, Cash $116.4M as BARDA Follow-On Awaited
SIGA sits 15% above its 52-week low of $2.83.
Summary
SIGA's Q3 10-Q confirms the already-reported $1.3M revenue and $2.9M net loss, with cash down to $116.4M and the business hinging on a new U.S. TPOXX procurement contract that has not yet been signed.
Key Events · Earnings and Guidance · SIGA
-
Q3 Revenue Collapses to $1.3M
Third-quarter total revenue was $1.3M versus $2.6M a year ago, with product sales of just $0.2M against $0.9M; nine-month revenue fell to $48.6M from $90.8M.
-
Net Loss of $2.9M in Q3
Q3 net loss was $2.9M, or $0.04 per diluted share, versus a $6.4M loss a year ago; nine-month net income was $6.1M versus $28.7M.
-
Cash Falls to $116.4M
Cash and equivalents were $116.4M at September 30, 2026, down from $155.0M at December 31, 2025, after the $0.60 per share special dividend paid in April 2026; management says liquidity covers at least twelve months.
-
Inventory Hinges on Follow-On Contract
The company carries $41.6M of inventory and warns that significant delays in securing a new U.S. government procurement contract, or terms different from prior contracts, could materially impact recoverability.
Analysis · SIGA · Life Sciences
The headline numbers were already out via the same-day 8-K, but the 10-Q is where the balance-sheet reality sits: cash fell to $116.4M from $155.0M at year-end after the $0.60 special dividend, and the company is now running on a thin revenue base while it waits for a new U.S. government TPOXX procurement contract. Nine-month revenue of $48.6M versus $90.8M a year ago shows how much of the business was the winding-down 19C BARDA deliveries. Management says liquidity covers at least the next twelve months, but the inventory note explicitly warns that a delayed or differently-termed follow-on contract could impair the $41.6M of inventory carried on the books. Two other items matter: BARDA added $2.07M to fund removing red dye from the capsules (a small regulatory fix, not a new procurement), and Chief Scientific Officer Dennis Hruby retires effective today, moving to a $20,000/month consulting role through May 2028 with roughly $1.8M of Q4 charges.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SIGA was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $234.2M. The 52-week trading range was $2.83 to $7.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.